A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
Renée C.G. de Bruin(Amsterdam UMC Location Vrije Universiteit Amsterdam), John P. Veluchamy(Amsterdam UMC Location Vrije Universiteit Amsterdam), Sinéad M. Lougheed(Amsterdam UMC Location Vrije Universiteit Amsterdam), Famke L. Schneiders(Amsterdam UMC Location Vrije Universiteit Amsterdam), Silvia Lopez‐Lastra(Université Paris-Sud), Roeland Lameris(Amsterdam UMC Location Vrije Universiteit Amsterdam), Anita G.M. Stam(Amsterdam UMC Location Vrije Universiteit Amsterdam), Zsolt Sebestyén(Heidelberg University), Jürgen Kuball(Heidelberg University), Carla F.M. Molthoff(Amsterdam UMC Location Vrije Universiteit Amsterdam), Erik Hooijberg(Amsterdam UMC Location Vrije Universiteit Amsterdam), Rob C. Roovers(Utrecht University), James P. Di Santo(Inserm), Paul M.P. van Bergen en Henegouwen(Utrecht University), Henk M.W. Verheul(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tanja D. de Gruijl(Amsterdam UMC Location Vrije Universiteit Amsterdam), Hans J. van der Vliet(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 84Open Access
Abstract
tumor mutation status and common Vγ9Vδ2-T cell receptor sequence variations. In combination with the conserved monomorphic nature of the Vγ9Vδ2-TCR and the facile replacement of the tumor-specific nanobody, this immunotherapeutic approach can be applied to a large group of cancer patients.
Related Papers
No related papers found
Powered by citation graph analysis